

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

Third Quarter Financial Statement (*) And Dividend Announcement

1(a) Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income

	Note	The Group					
		3-month period from 1 July to 30 September 2026 RMB'000	3-month period from 1 July to 30 September 2025 RMB'000	Change %	9-month period from 1 January to 30 September 2026 RMB'000	9-month period from 1 January to 30 September 2025 RMB'000	Change %
Revenue	2	963,217	1,019,342	(6)	3,417,808	3,669,861	(7)
Cost of sales	2	(238,857)	(262,446)	(9)	(866,639)	(977,280)	(11)
Gross profit		724,360	756,896	(4)	2,551,169	2,692,581	(5)
Interest income		2,209	32,751	(93)	7,635	37,491	(80)
Dividend income		-	-	-	92	92	-
Other gains		8,427	23,043	(63)	43,424	1,626,434	(97)
Marketing and distribution costs		(227,371)	(396,609)	(43)	(1,026,000)	(1,417,151)	(28)
Research and development costs		(44,809)	(43,070)	4	(124,762)	(104,622)	19
Administrative expenses		(131,752)	(120,243)	10	(335,591)	(310,862)	8
Finance costs		(88)	(149)	(41)	(401)	(567)	(29)
Other losses		(18,792)	(1,841)	n.m	(69,456)	(22,804)	n.m
Share of profit/(loss) of associates		(3,961)	2,408	n.m	14,458	19,619	(26)
Profit before income tax		308,223	253,187	22	1,060,568	2,520,211	(58)
Income tax expense	3	(39,061)	(30,061)	30	(147,833)	(373,994)	(60)
Profit, net of tax		269,162	223,126	21	912,735	2,146,217	(57)

	Note	The Group					
		3-month period from 1 July to 30 September 2026 RMB'000	3-month period from 1 July to 30 September 2025 RMB'000	Change %	9-month period from 1 January to 30 September 2026 RMB'000	9-month period from 1 January to 30 September 2025 RMB'000	Change %
Other comprehensive income Items that will not be reclassified to profit or loss:							
Change in fair Value of equity investment at FVTOCI, net of tax		-	-	-	-	(78)	n.m
Share of other comprehensive (loss)/ income from equity-accounted associates, net of tax		2,110	(148)	n.m	2,949	(227)	n.m
Other Comprehensive Income Items that may be reclassified subsequently to profit or loss:							
Other reserve reclassified to profit or loss upon disposal of equity interests in an associate, net of tax		-	-	-	(2,234)	(600)	n.m
Total Other Comprehensive (loss)/ income, Net of Tax		2,110	(148)	n.m	715	(905)	n.m
Total comprehensive income		271,272	222,978	22	913,450	2,145,312	(57)

	Note	The Group					
		3-month period from 1 July to 30 September 2026 RMB'000	3-month period from 1 July to 30 September 2025 RMB'000	Change %	9-month period from 1 January to 30 September 2026 RMB'000	9-month period from 1 January to 30 September 2025 RMB'000	Change %
Profit, net of tax attributable to:							
Owners of the parent		272,081	224,560	21	916,833	2,152,183	(57)
Non-controlling interests		(2,919)	(1,433)	n.m	(4,098)	(5,966)	(31)
		269,162	223,127	21	912,735	2,146,217	(57)
Total comprehensive income attributable to:							
Owners of the parent		274,191	224,412	22	917,548	2,151,278	(57)
Non-controlling interests		(2,919)	(1,433)	n.m	(4,098)	(5,966)	(31)
		271,272	222,979	22	913,450	2,145,312	(57)
Earnings per ordinary share for the period based on net profits after deducting any provision for preference dividends:							
Based on weighted average number of ordinary share on issue		0.35	0.30	17	1.19	2.80	(58)

(*) prepared under International Financial Reporting Standards

n.m Not Meaningful

Additional information on the Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income. The following significant items of gains / (charges) were included in the statement of income.

	<u>The Group</u>					
	3-month period from 1 July to 30 September 2026 RMB'000	3-month period from 1 July to 30 September 2025 RMB'000	Change %	9-month period from 1 January to 30 September 2026 RMB'000	9-month period from 1 January to 30 September 2025 RMB'000	Change %
Profit, net of tax is arrived at after crediting / (charging):						
Other income (including government grant)	8,499	19,602	(57)	41,198	62,570	(34)
Interest income	2,209	32,751	(93)	7,635	37,491	(80)
Interest on borrowings	(88)	(149)	(41)	(401)	(567)	(29)
Allowance for impairment on trade receivables – reversal / (loss)	(8,625)	299	n.m	(15,570)	(9,177)	70
Allowance for impairment on other receivables – reversal / (loss)	(456)	67	n.m	(384)	(459)	(16)
Allowance for impairment of notes receivables						
Impairment loss on inventories	(8,183)	(2,028)	n.m	(50,339)	(10,535)	n.m
Foreign currency translation losses, net	(1,607)	(493)	n.m	(2,107)	(452)	n.m
Gain/(loss) on disposal of property, plant and equipment, intangible assets and other non-current assets	(29)	3,483	n.m	(210)	3,558	n.m
Investment income – Dividend income	-	-	-	92	92	-
Proceeds from disposal of a subsidiary	-	-	-	-	17,377	n.m
Proceeds from disposal of an associate	-	-	-	2,226	1,542,929	n.m
Share-based payments						

Depreciation and amortisation	(30,498)	(28,264)	8	(91,410)	(87,416)	5
-------------------------------	----------	----------	---	----------	----------	---

1(b)(i) Condensed Interim Statements of Financial Position

		The Group			The Company		
	Note	As at 30 September 2026 RMB'000	As at 31 December 2025 RMB'000	Change %	As at 30 September 2026 RMB'000	As at 31 December 2025 RMB'000	Change %
ASSETS							
Non-current assets							
Property, plant and equipment		1,106,897	1,133,999	(2)	892,650	914,299	(2)
Right-of-use assets		9,429	7,548	25	2,756	1,861	48
Investment properties		111,636	110,367	1	111,636	110,367	1
Land use rights		219,277	224,507	(2)	187,313	191,776	(2)
Intangible assets		97,406	86,639	12	91,299	78,966	16
Goodwill	12						
Investment in subsidiaries	7				933,404	933,404	-
Investment in associates	8	1,194,464	1,165,662	2	1,194,464	1,165,662	2
Other financial assets	9	1,177,372	1,427,139	(18)	1,065,091	1,273,018	(16)
Deferred tax assets		331,462	341,007	(3)	303,828	315,253	(4)
Other non-financial assets	10	47,007	38,347	23	36,543	30,762	19
Total non-current assets		4,294,950	4,535,215	(5)	4,818,984	5,015,368	(4)
Current assets							
Inventories		1,140,529	1,132,968	1	1,040,102	1,026,147	1
Trade and other receivables	11	1,457,700	1,603,694	(9)	1,310,002	1,456,156	(10)
Other financial assets	9	436,104	3,316,008	(87)	231,316	3,191,129	(93)
Other non-financial assets	10	90,277	85,422	6	67,060	66,133	1
Cash and cash equivalents		1,314,441	1,016,427	29	1,045,390	765,339	37
Total current assets		4,439,051	7,154,519	(38)	3,693,870	6,504,904	(43)
Total assets		8,734,001	11,689,734	(25)	8,512,854	11,520,272	(26)

		<u>The Group</u>			<u>The Company</u>		
		As at 30 September 2026 RMB'000	As at 31 December 2025 RMB'000	Change %	As at 30 September 2026 RMB'000	As at 31 December 2025 RMB'000	Change %
EQUITY							
Equity							
Share capital	13	770,094	770,094	-	770,094	770,094	-
Share premium		1,206,930	1,206,930	-	1,206,930	1,206,930	-
Retained earnings		4,117,158	5,002,346	(18)	3,726,386	4,681,566	(20)
Other reserves		120,844	120,129	1	535,493	534,778	0
Total equity attributable to equity holders of the Company		6,215,026	7,099,499	(12)	6,238,903	7,193,368	(13)
Non-controlling interests		(3,652)	446	n.m	-	-	-
Total equity		6,211,374	7,099,945	(13)	6,238,903	7,193,368	(13)
LIABILITIES							
Non-current liabilities							
Deferred tax liabilities		176	276	(36)	-	-	-
Trade payables		2,399	2,399	-	2,259	2,259	-
Lease liabilities		4,800	4,658	3	1,123	510	n.m
Other non-financial liabilities		81,322	76,018	7	67,948	63,067	8
Total non-current liabilities		88,697	83,351	6	71,330	65,836	8
Current liabilities							
Income tax payable		33,734	29,216	15	25,553	25,192	1
Trade and other payables	15	2,088,013	4,212,730	(50)	1,893,139	3,991,547	(53)
Other financial liabilities	14	86,026	57,903	49	71,352	48,864	46
Lease liabilities		4,085	3,125	31	1,097	1,190	(8)
Other non-financial liabilities		222,072	203,464	9	211,480	194,275	9
Total current liabilities		2,433,930	4,506,438	(46)	2,202,621	4,261,068	(48)
Total liabilities		2,522,627	4,589,789	(45)	2,273,951	4,326,904	(47)
Total equity and liabilities		8,734,001	11,689,734	(25)	8,512,854	11,520,272	(26)

1(b)(ii) Condensed Interim Statements of Changes in Equity

All in RMB'000

Group	Share capital	Share premium	Other reserves	Retained earnings	Parent sub-total	Non-controlling interests	Total equity
Balance at 1 January 2026	770,094	1,206,930	120,129	5,002,346	7,099,499	446	7,099,945
Total comprehensive income for the period	-	-	715	916,833	917,548	(4,098)	913,450
Dividends	-	-	-	(1,802,021)	(1,802,021)	-	(1,802,021)
Balance at 30 September 2026	770,094	1,206,930	120,844	4,117,158	6,215,026	(3,652)	6,211,374

Group	Share capital	Share premium	Other reserves	Retained earnings	Parent sub-total	Non-controlling interests	Total equity
Balance at 1 January 2025	770,094	1,206,930	122,794	5,743,776	7,843,594	6,344	7,849,938
Total comprehensive income for the period	-	-	(905)	2,152,183	2,151,278	(5,966)	2,145,312
Dividends	-	-	-	(985,721)	(985,721)	-	(985,721)
Liquidation of a subsidiary	-	-	194	-	194	14,376	14,570
Balance at 30 September 2025	770,094	1,206,930	122,083	6,910,238	9,009,345	14,754	9,024,099

All in RMB'000

Company	Share capital	Share premium	Other reserves	Retained earnings	Total equity
Balance at 1 January 2026	770,094	1,206,930	534,778	4,681,566	7,193,368
Total comprehensive income for the period	-	-	715	846,841	847,556
Dividends	-	-	-	(1,802,021)	(1,802,021)
Balance at 30 September 2026	770,094	1,206,930	535,493	3,726,386	6,238,903

Company	Share capital	Share premium	Other reserves	Retained earnings	Total equity
Balance at 1 January 2025	770,094	1,206,930	537,637	5,531,353	8,046,014
Total comprehensive income for the period	-	-	(905)	2,062,719	2,061,814
Dividends	-	-	-	(985,721)	(985,721)
Balance at 30 September 2025	770,094	1,206,930	536,732	6,608,351	9,122,107

1(c) Condensed Interim Consolidated Statement of Cash Flows

	<u>The Group</u>			
	3-month period from 1 July to 30 September 2026 RMB'000	3-month period from 1 July to 30 September 2025 RMB'000	9-month period from 1 January to 30 September 2026 RMB'000	9-month period from 1 January to 30 September 2025 RMB'000
<u>Cash flows from operating activities</u>				
Profit before income tax	308,223	253,187	1,060,568	2,520,211
Interest income	(2,209)	(32,751)	(7,635)	(37,491)
Interest expense	88	149	401	567
Dividend income	-	-	(92)	(92)
Other gains	(7,666)	(17,632)	(36,202)	(47,767)
Share of (profit)/ loss of equity-accounted associates	3,961	(2,408)	(14,458)	(19,619)
Depreciation and amortisation of property, plant and equipment, investment properties, land use rights and intangible assets	30,498	28,264	91,410	87,416
Gain on disposals of property, plant and equipment, intangible assets and other non-current assets	29	(3,483)	210	(3,558)
Impairment on trade, other receivables – loss / (reversal) and impairment loss on inventory	17,264	1,661	66,293	20,170
Share-based payments				
Proceeds from disposal of a subsidiary	-	-	-	(17,377)
Proceeds from disposal of an associate	-	-	(2,226)	(1,542,929)
Operating cash flows before changes in working capital	350,188	226,987	1,158,269	959,531

	The Group			
	3-month period from 1 July to 30 September 2026 RMB'000	3-month period from 1 July to 30 September 2025 RMB'000	9-month period from 1 January to 30 September 2026 RMB'000	9-month period from 1 January to 30 September 2025 RMB'000
Inventories	(32,968)	15,531	(44,953)	83,764
Trade and other receivables	32,666	191,415	159,024	(286,663)
Other assets	72	(71,643)	(23,543)	(59,382)
Trade and other payables	(310,949)	(195,901)	(287,773)	119,739
Cash restricted in use	(2,254)	-	(2,484)	-
Other liabilities	14,921	(49,475)	23,912	(112,521)
Net cash flows from operations	51,677	116,914	982,452	704,468
Income tax paid	(29,950)	(281,861)	(134,061)	(642,803)
Net cash flows generated from/ (used in) operating activities	21,727	(164,947)	848,391	61,665
Cash flows from investing activities				
Purchase of property, plant and equipment, intangibles, land use rights and investment properties	(43,080)	(21,063)	(78,497)	(62,879)
Acquisition of financial assets	(30,000)	(1,755,000)	(2,065,000)	(4,425,000)
Acquisition of subsidiary (net of cash acquired)	-	-	-	(31,706)
Proceeds from disposal of financial assets	700,004	300,000	5,172,594	3,483,467
Dividends income received from associates and financial assets	-	2,400	3,092	2,492
Proceeds from disposals of property, plant and equipment, intangible assets and other assets	-	295	134	359
Interest income received	3,711	38,538	83,415	55,440
Net cash flows generated from/(used in) investing activities	630,635	(1,434,830)	3,115,738	(977,827)

	The Group			
	3-month period from 1 July to 30 September 2026 RMB'000	3-month period from 1 July to 30 September 2025 RMB'000	9-month period from 1 January to 30 September 2026 RMB'000	9-month period from 1 January to 30 September 2025 RMB'000
<u>Cash flows from financing activities</u>				
Cash Received from Minority Shareholders for Subsidiary Equity Absorption	-	-	-	-
Increase in new loans and borrowings	-	5,000	-	5,000
Dividends paid to equity owners	(1,784,781)	(981,085)	(3,661,990)	(981,085)
Interest paid	(2)	(30)	(80)	(62)
Loans and borrowings paid	(2,300)	(2,000)	(2,300)	(2,000)
Repayment of borrowings and lease liabilities	(729)	(421)	(3,370)	(1,381)
Net cash flows used in financing activities	(1,787,812)	(978,536)	(3,667,740)	(979,528)
Net increase/ (decrease) in cash and cash equivalents	(1,135,450)	(2,578,313)	296,389	(1,895,690)
Unrealised foreign exchange adjustments	(166)	(59)	(859)	(58)
Cash and cash equivalents, consolidated statement of cash flows, beginning balance	2,447,573	3,627,057	1,016,427	2,944,433
Cash and cash equivalents, consolidated statement of cash flows, ending balance	1,311,957	1,048,685	1,311,957	1,048,685

Notes to the Condensed Interim Financial Statements

30 September 2026

1. General

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “**Company**”) is incorporated in the People’s Republic of China (the “**PRC**”) as a joint stock limited company. The Company is listed on the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) and the Shanghai Stock Exchange (the “**SSE**”).

The financial statements are presented in Chinese Renminbi (“**RMB**”) and have been rounded to the nearest thousand (“**RMB’000**”) unless when otherwise indicated, and they cover the Company and its subsidiaries (collectively, the “**Group**”), and the Group’s interests in associates.

The board of directors of the Company had, on 29 October 2026, approved and authorised these condensed interim financial statements for announcement on SGXNET.

The principal activities of the Group are disclosed in Note 2 on segment information.

The registered office of the Company is located at 17 Baidi Road, Nankai District, Tianjin, the PRC 300193. The principal place of business of the Company is in Tianjin, the PRC.

The financial information contained in this announcement has neither been audited nor reviewed by the auditors.

The latest audited annual financial statements were not subject to an adverse opinion, qualified opinion or disclaimer of opinion.

The Company is not required to announce its quarterly financial statements on SGXNET pursuant to the requirements of the listing manual of the SGX-ST (the “**Listing Manual**”). However, since the Company is required to announce its quarterly financial statements in accordance with the requirements of the SSE, the Company is voluntarily announcing its quarterly financial statements on SGXNET.

These condensed consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards issued by the International Accounting Standards Board and the provisions of the SGX Mainboard Listing Rules.

The accounting policies and methods of computation applied in these condensed consolidated interim financial statements are consistent with those of the latest audited annual financial statements. However, the typical notes and information included in the latest audited annual

financial statements are not included in these interim financial statements except for the selected explanatory notes included to explain events and transactions that are significant to an understanding of the changes in the performance and financial position of the Group since the latest audited annual financial statements.

The estimates and assumptions contained in these condensed consolidated interim financial statements are periodically monitored to ensure that they incorporate all relevant information available at the date when the financial statements are prepared. However, this does not prevent actual figures differing from estimates. The nature and the carrying amount of such significant assets and liabilities are disclosed with further details in the relevant Notes to these condensed consolidated interim financial statements.

2. Financial information by operating segments

2A. Information about reportable segment profit or loss

For management purposes, the Group is segregated into the Chinese Medicine, Western Medicine and Raw Chinese Medicine & Pieces major strategic operating segments.

2B. Profit or loss from continuing operations and reconciliations

	<u>Chinese medicine</u>	<u>Western medicine</u>	<u>Raw Chinese Medicine & Pieces</u>	<u>Other</u>	<u>Total</u>
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
9-month period ended 30 September 2026					
Revenue	3,134,496	43,071	195,161	45,080	3,417,808
Cost of sales	(703,226)	(25,210)	(116,238)	(21,965)	(866,639)
Gross profit	2,431,270	17,861	78,923	23,115	2,551,169
9-month period ended 30 September 2025					
Revenue	3,376,667	47,184	213,865	32,145	3,669,861
Cost of sales	(794,456)	(25,501)	(141,316)	(16,007)	(977,280)
Gross profit	2,582,211	21,683	72,549	16,138	2,692,581

2C. Disaggregation of revenue from contracts with customers

	<u>Group</u>	
	9-month period ended 30 September 2026 RMB'000	9-month period ended 30 September 2025 RMB'000
Sale of goods recognised at point in time	3,408,129	3,667,929
Revenue recognised over time	9,679	1,932
	3,417,808	3,669,861

3. Income tax

3A. Components of tax expense (income) recognised in profit or loss

	<u>Group</u>	
	9-month period ended 30 September 2026 RMB'000	9-month period ended 30 September 2025 RMB'000
<u>Current income tax</u>		
Current income tax	138,389	379,846
<u>Deferred tax</u>		
Deferred tax	9,444	(5,852)
	147,833	373,994

3B. Adjustments for current income tax

	<u>Group</u>	
	9-month period ended 30 September 2026 RMB'000	9-month period ended 30 September 2025 RMB'000
Profit / (Loss) before tax	1,060,568	2,520,211
Less: Share of profit of equity-accounted associates	(14,458)	(19,619)
	1,046,110	2,500,592
Income tax expense at the above rate	261,528	625,148
Effect of concessionary tax rate at 15%	(104,331)	(249,607)
Non-deductible items	1,838	4,479
Non-taxable items	-	-
Tax incentive	(16,097)	(10,425)
Unrecognised deferred tax assets	4,895	4,399
	147,833	373,994

4. Disposal of subsidiaries/ associated companies

There was no disposal of subsidiaries for the current financial period reported on.

In particular, for the purposes of Rule 706A of the Listing Manual, for the current financial period reported on, the Group had not disposed of shares resulting in a company ceasing to be a subsidiary or an associated company of the Company and had also not disposed of shares resulting in the Company reducing its shareholding percentage in a subsidiary or an associated company.

For completeness, Tianjin Bio-Chip Co. (天津生物芯片技术有限责任公司) (“**Bio-Chip Co.**”), an associated company in which the Company held a 26.4% equity interest, was placed into liquidation during the current financial period reported on, and the liquidation was completed before 30 June 2026. Accordingly, Bio-Chip Co. has ceased to be an associated company of the Company.

5. Dividends on equity shares

	9-month period ended 30 September 2026		9-month period ended 30 September 2025	
	Final dividend (FY2025)	Interim dividend (FY2025)	Final dividend (FY2024)	Interim dividend (FY2024)
Type	Cash	Cash	Cash	-
Dividend rate	RMB 2.34 per ordinary share	RMB 2.45 per ordinary share	RMB 1.28 per ordinary share	-
Record date	30 June 2026	2 February 2026	26 June 2025	-
Date paid or payable	10 July 2026	12 February 2026	4 July 2025	-

The total dividends paid on ordinary shares for the financial year ended 31 December 2025 (“FY2025”) were RMB 3,688,751,965.24, comprising the interim dividend of RMB 1,886,731,172.20 and the final dividend of RMB 1,802,020,793.04 (FY2024: RMB 985,802,593.28).

6. Acquisition of subsidiaries / subsidiary / business combination

There was no company which became a subsidiary of the Company through acquisition or business combination for the current financial period reported on.

In particular, for the purposes of Rule 706A of the Listing Manual, for the current financial period reported on, the Group had not acquired any shares of a company resulting in such company becoming a subsidiary or an associated company of the Company and had also not acquired any shares resulting in the Company increasing its shareholding percentage in a subsidiary or an associated company.

7. Investments in subsidiaries

	<u>Company</u>	
	As at 30 September 2026 RMB'000	As at 31 December 2025 RMB'000
Movements during the period:		
At beginning of the period	933,404	1,048,534
Additions	-	3,000
Reductions	-	(118,130)
At the end of the period	933,404	933,404

8. Investments in associates

	<u>Group</u>	
	As at 30 September 2026 RMB'000	As at 31 December 2025 RMB'000
Movements in carrying value:		
At beginning of the period	1,165,662	1,293,528
Share of profit of associates	46,452	(21,966)
Dividends	(3,000)	(14,400)
Additions	-	-
Disposals	(17,599)	(80,537)
Other equity movements	2,949	(10,963)
At end of the period	1,194,464	1,165,662

9. Other financial assets

	<u>Group</u>	
	As at 30 September 2026	As at 31 December 2025
	RMB'000	RMB'000
Other financial assets - current assets		
Investment in debt instruments at amortised cost	436,104	3,316,008
Other financial assets - non-current assets		
Investment in debt instruments at amortised cost	1,177,372	1,427,139
Investment in equity instruments at fair value through other comprehensive income	-	-
	1,177,372	1,427,139
	1,613,476	4,743,147

10. Other non-financial assets

	<u>Group</u>	
	As at 30 September 2026	As at 31 December 2025
	RMB'000	RMB'000
Current assets		
Prepayments	33,393	32,912
Right of return assets	5,844	6,542
Value-added taxes recoverable	49,964	45,116
Income tax recoverable	1,076	852
	90,277	85,422
Non-current assets		
Prepayment	47,007	38,347
	137,284	123,769

11. Trade and other receivables

	<u>Group</u>	
	As at 30 September 2026	As at 31 December 2025
	RMB'000	RMB'000
Trade receivables		
Bills receivable	547,269	598,111
Third parties	765,872	704,044
Associates	73,331	151,749
Related parties	160,903	223,877
Less: Allowance for credit impaired	(17,617)	(17,666)
Less: Allowance for expected credit losses	(104,418)	(88,800)
	1,425,340	1,571,315
Other receivable		
Dividend receivable	3,016	3,016
Third parties	46,734	47,545
Associates	17,522	17,522
Related parties	4,418	3,215
Less: Allowance for expected credit losses	(39,330)	(38,919)
	32,360	32,379
Total	1,457,700	1,603,694

The ageing of the trade receivables balances was as follows:

	<u>Group</u>		
	<u>Gross amount</u> RMB'000	<u>ECL</u> %	<u>Loss allowance</u> RMB'000
As at 30 September 2026			
Within 1 year	805,294	0.13	1,042
1 – 2 years	80,613	20	16,123
2 – 3 years	18,658	50	9,329
Over 3 years	77,924	100	77,924
Total	982,489		104,418
As at 31 December 2025			
Within 1 year	946,369	0.13	1,227
1 – 2 years	30,853	20	6,171
2 – 3 years	6,761	50	3,381
Over 3 years	78,021	100	78,021
Total	1,062,004		88,800

12. Goodwill

	<u>Group</u>	
	As at 30 September 2026 RMB'000	As at 31 December 2025 RMB'000
Movement during the financial period:		
Beginning balance	-	12,301
Additions	-	-
Reductions	-	(12,301)
Ending balance	-	-

13. Share capital and treasury shares

	<u>Group</u>			
	Number of ordinary shares		Amount of share capital	
	As at 30 September 2026 '000	As at 31 December 2025 '000	As at 30 September 2026 RMB'000	As at 31 December 2025 RMB'000
Movements in share capital:				
At beginning of the period	770,094	770,094	770,094	770,094
Restricted A-Shares buy-back	-	-	-	-
At end of the period	770,094	770,094	770,094	770,094

There has been no change in the Company's share capital since the end of the previous period reported on, being 30 June 2026.

The Company does not have any shares that may be issued on conversion of any outstanding convertibles as at 30 September 2026 and 30 September 2025.

The Company does not hold any treasury shares and there are no subsidiary holdings as at 30 September 2026 and 30 September 2025.

	As at 30 September 2026	As at 31 December 2025
Number of issued shares excluding treasury shares	770,094,356	770,094,356
Number of treasury shares held	Nil	Nil

14. Aggregate amount of the group's borrowings and debt securities

	<u>Secured</u>		<u>Unsecured</u>	
	As at 30	As at 31	As at 30	As at 31
	September	December	September	December
	2026	2025	2026	2025
	RMB'000	RMB'000	RMB'000	RMB'000
<u>Repayable in</u>				
<u>one year or</u>				
<u>less, or on</u>				
<u>demand:</u>				
Bank				
borrowings	2,700	5,000	83,326	52,903
Subtotal	2,700	5,000	83,326	52,903
<u>Repayable after</u>				
<u>one year:</u>				
Bank				
borrowings	-	-	-	-
Subtotal	-	-	-	-
Total	2,700	5,000	83,326	52,903

14A. Details of any collaterals

The secured bank borrowings disclosed above, with an aggregate principal amount of RMB 2.7 million, are secured by two (2) properties owned by NewScen Coast Bio-Pharmaceutical Co., Ltd. (天津中新科炬生物制药股份有限公司), a subsidiary of the Company, with such properties valued at approximately RMB 11,309,376.17 in aggregate as at 30 September 2026.

15. Trade and other payables

	<u>Group</u>	
	As at 30 September 2026	As at 31 December 2025
	RMB'000	RMB'000
Trade payables		
Bills payable	-	-
Outside parties	203,082	213,930
Associates	3,971	3,332
Related parties	531	792
Employee benefits payables	232,998	225,051
	440,582	443,105
Other payables		
Outside parties	1,499,095	1,753,631

taxes payables	80,638	86,719
Dividend payable	51,393	1,919,093
Associates	-	-
Related parties	16,305	10,182
Subtotal	1,647,431	3,769,625
Total	2,088,013	4,212,730

16. Capital commitments

	Group	
	As at 30 September 2026 RMB'000	As at 31 December 2025 RMB'000
Contractual obligations to purchase and construct	6,862	17,938

17. Categories of financial assets and liabilities

	Group	
	As at 30 September 2026 RMB'000	As at 31 December 2025 RMB'000
Financial assets		
Financial assets at amortised cost	4,385,617	7,363,268
Financial assets at fair value through other comprehensive income	-	-
	4,385,617	7,363,268
Financial liabilities		
Financial liabilities at amortised cost	2,099,297	4,222,912

18. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied

The Group has applied the same accounting policies and method of computation as presented in the audited financial statements of the Group for the reporting year ended 31 December 2025.

19. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends:

(a) Based on the weighted average number of ordinary shares on issue; and

(b) On a fully diluted basis (detailing any adjustments made to the earnings)

	Group	
	9-month period ended 30 September 2026	9-month period ended 30 September 2025
	RMB	RMB
Based on weighted average number of ordinary shares in issue	1.19	2.80

Diluted earnings per share is the same as basic earnings per share as the Company does not have any potential ordinary shares that have a dilutive effect on earnings per share as at the end of the period reported on.

20. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the:

(a) current financial period reported on; and

(b) immediately preceding financial year.

	Group		Company	
	As at 30 September 2026	As at 31 December 2025	As at 30 September 2026	As at 31 December 2025
	RMB	RMB	RMB	RMB
Net asset value per ordinary share based on existing issued share capital as at the end of the period reported on	8.07	9.22	8.10	9.34

21. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business.

The financial performance is not significantly affected by any of the seasonality or cyclicalities of interim operations.

(a) Revenue:

The Group's revenue in the third quarter of the financial year ending 31 December 2026 ("FY2026") ("3Q FY2026") was approximately RMB 963 million, a decrease of approximately RMB 56 million, or 6%, from approximately RMB 1,019 million in the third quarter of FY2025 ("3Q FY2025"). For the 9-month period ended 30 September 2026 ("9M 2026"), the Group recorded a revenue of approximately RMB 3,418 million, a decrease of approximately RMB 252 million, or approximately 7% over the 9-month period ended 30 September 2025 ("9M 2025").

(b) Gross Profit Margin:

The Group's gross profit in 3Q FY2026 decreased by approximately 4% from approximately RMB 757 million in 3Q FY2025 to approximately RMB 724 million. For 9M 2026, the Group's gross profit was approximately RMB 2,551 million compared to approximately RMB 2,693 million in the corresponding period of FY2025. The gross profit margin has increased from 73% in 9M 2025 to 75% in 9M 2026, an increase of approximately 2 percentage points year-on-year.

(c) Other Gains:

Other gains in 3Q FY2026 were approximately RMB 8 million. For 9M 2026, the Group's other gains were approximately RMB 43 million, a decrease of approximately RMB 1,583 million over the previous corresponding period. The decrease was mainly attributable to the absence in 9M 2026 of the following one-off gains recognised in 9M 2025: (i) the gain of approximately RMB 1,542.93 million from the disposal of the remaining 12% equity interest in Sino-American Tianjin SmithKline & French Lab., Ltd. (中美天津史克制药有限公司) ("**Sino-American Tianjin**"), a former associated company of the Company, in 9M 2025; and (ii) the recognition of a disposal gain of approximately RMB 17.38 million following the court's ruling for acceptance of the application for the bankruptcy liquidation of Tianjin Shin Poong Pharmaceutical Co., Ltd. (天津新丰制药有限公司), a former subsidiary of the Company, which has been subsequently excluded from the Group's consolidated financial statements with effect from 22 May 2025, being the date on which the bankruptcy administrator was appointed by the court, partially offset by a gain of approximately RMB 2 million arising from the liquidation of Bio-Chip Co., a former associated company of the Company, in 9M 2026.

(d) Major Expenses:

(i) Marketing and distribution costs in 3Q FY2026 were approximately RMB 227 million, a

decrease of approximately RMB 169 million, or 43%, over the previous corresponding period of approximately RMB 397 million. For 9M 2026, marketing and distribution costs decreased by approximately RMB 391 million, or 28%, from approximately RMB 1,417 million in 9M 2025 to approximately RMB 1,026 million. The decrease was mainly due to lower revenue, changes in the product mix, and the optimisation of selling expenses through the deepening of marketing reforms and more targeted marketing strategies.

(ii) Research and Development (“**R&D**”) costs in 3Q FY2026 were approximately RMB 45 million, an increase of approximately RMB 2 million or 4% over the previous corresponding period. For 9M 2026, the R&D costs increased by approximately RMB 20 million, or 19% from approximately RMB 105 million in 9M 2025 to approximately RMB 125 million. This was mainly due to an increase in R&D investment compared to the same period in FY2025.

(iii) Administrative expenses in 3Q FY2026 increased by approximately RMB 12 million, from approximately RMB 120 million in 3Q FY2025. For 9M 2026, the administrative expenses were approximately RMB 336 million, an increase of approximately RMB 25 million. The increase was mainly due to the Company’s higher year-on-year investment in brand promotion activities.

(iv) Finance costs in 3Q FY2026 decreased by approximately RMB 0.06 million, while for 9M 2026, the finance costs decreased by approximately RMB 0.17 million from approximately RMB 0.57 million in 9M 2025 to approximately RMB 0.40 million.

(v) Other losses in 3Q FY2026 increased by approximately RMB 17 million, while for 9M 2026, other losses were approximately RMB 69 million, an increase of approximately RMB 47 million. The increase was mainly due to higher allowance for inventory impairment recognised as compared to the previous corresponding period.

(e) Share of results of associated companies:

The Group recorded a share of losses of associated companies of approximately RMB 4 million in 3Q FY2026, a decrease of approximately RMB 6 million over the previous corresponding period. The Group’s share of profits of associated companies in 9M 2026 was approximately RMB 14 million, a decrease of approximately RMB 5.2 million or 26% over the previous corresponding period. The decrease was mainly due to the lower share of profit from Tianjin Hong Ren Tang Pharmaceutical Co., Ltd. (天津宏仁堂药业有限公司) as compared to the previous corresponding period.

(f) Total comprehensive income:

The Group’s total comprehensive income (net of tax) in 3Q FY2026 was approximately RMB 271 million, an increase of 22% over the previous corresponding period. The Group’s total comprehensive income (net of tax) in 9M 2026 was approximately RMB 913 million, a decrease of approximately RMB 1,232 million or 57% over the previous corresponding period. The decrease was mainly due to the absence of a one-off net gain after tax of approximately

RMB1,308.15 million recognised in 9M 2025 from the disposal of the remaining 12% equity interest in Sino-American Tianjin.

The profit attributable to equity holders of parent (net of tax) in 3Q FY2026 was approximately RMB 272 million, an increase of 21% over the previous corresponding period. The profit attributable to equity holders of parent (net of tax) in 9M 2026 was approximately RMB 917 million, a decrease of approximately RMB 1,235 million, or 57% from approximately RMB 2,152 million of the corresponding period in 9M 2025.

(g) Major changes in statement of financial positions:

(i) As at 30 September 2026, the Group's cash and cash equivalents amounted to approximately RMB 1,314 million, which was an increase of approximately RMB 298 million, or 29% from approximately RMB 1,016 million over the balance as at 31 December 2025.

(ii) Trade and other receivables decreased by approximately 9% or approximately RMB 146 million from approximately RMB 1,604 million at the beginning of the financial year to approximately RMB 1,458 million as at 30 September 2026.

(iii) Inventories were approximately RMB 1,141 million as at 30 September 2026, which was an increase of approximately RMB 8 million, or 1% over the balance as at 31 December 2025.

(iv) Other non-financial assets (current) increased by approximately RMB 5 million to approximately RMB 90 million as at 30 September 2026.

(v) Investment in associates of the Group increased by 2% or approximately RMB 29 million to approximately RMB 1,194 million as at 30 September 2026.

(vi) Other financial assets decreased by approximately RMB 3,130 million or 66% to approximately RMB 1,613 million as at 30 September 2026. The decrease was mainly due to the maturity of certain large-denomination certificates of deposit and similar deposit products during the current financial period reported on, the proceeds of which were applied towards the payment of dividends.

(vii) Property, plant and equipment decreased by approximately RMB 27 million to approximately RMB 1,107 million as at 30 September 2026.

(h) Change in cash flow position:

(i) In 9M 2026, the Group recorded net cash inflow from operating activities of approximately RMB 848 million, an increase of approximately RMB 787 million, compared to approximately RMB 62 million in the same period last year. The increase was mainly due to (i) the payment in 9M 2025 of income tax of approximately RMB 491.17 million arising from the disposal of the remaining 12% equity interest in the former associated company, Sino-American Tianjin; and

(ii) the year-on-year increase in cash received from the discounting of bank acceptance bills in 9M 2026.

(ii) In 9M 2026, the Group recorded net cash inflow from investing activities of approximately RMB 3,116 million, an increase of approximately RMB 4,094 million as compared to net cash outflows of approximately RMB 978 million in the same period last year. The change was mainly due to the receipt of proceeds upon the maturity of existing large-denomination certificates of deposit and other deposit products during the current financial period reported on.

(iii) In 9M 2026, the Group recorded net cash outflow from financing activities of approximately RMB 3,668 million, an increase of approximately RMB 2,688 million as compared to approximately RMB 980 million in 9M 2025. The increase was mainly due to the year-on-year increase in cash dividends paid during the current financial period reported on.

22. Forecast, or a prospect statement

There was no forecast or prospect statement that had been previously disclosed to shareholders.

23. Significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months

In 3Q 2026, the 15th Five-Year Plan for the Revitalisation and Development of Traditional Chinese Medicine (《中医药振兴发展“十五五”规划》) was issued, focusing on expanding coverage, improving quality, leveraging strengths and addressing shortcomings. The new National Essential Medicines List took effect on 1 September 2026, increasing the proportion of Chinese patent medicines and including Class 1 innovative traditional Chinese medicine (“TCM”) drugs for the first time. The fourth batch of national alliance-based procurement of Chinese patent medicines also entered implementation, covering over-the-counter (“OTC”) products on a large scale for the first time.

Supportive policies continue to create opportunities for the industry. Initiatives such as classical formula development platforms and TCM family doctor services are being rolled out, county-level TCM specialty development is accelerating, and grassroots healthcare channels are expanding, while time-honoured brands with exclusive products are receiving greater support. Demand is growing steadily, particularly in cardiovascular chronic disease management and medicine-food homology products amid population ageing, while digital tools are helping enterprises reach end-markets and consumers more directly. At the same time, the industry faces pressures: OTC prices and channel margins have declined following alliance-based procurement, and enterprises have become more rational in their pricing; price fluctuations in certain medicinal materials have raised raw material costs, and high barriers to overseas market entry and a shortage of multidisciplinary talent remain long-term challenges.

Against this backdrop, the Group has advanced its key initiatives under the theme of “Inheritance and Innovation, Quality Manufacturing for the Brand” (传承创新、品牌质造). In production, the Group optimised its medicinal material base layout, built a digital factory for Suxiao Jiuxin Pills, deepened “AI + TCM” (AI + 中药) applications and strengthened quality control across the industry chain. In market development, the Group launched the ten-city Suxiao Jiuxin Public Welfare Campaign 3.0, set up “Caring Suxiao” first-aid stations, developed a cardiac health AI agent, sponsored TCM cultural fairs and expanded its “Yangsheng Fang” (养生坊) store network. In internationalisation, Angong Niu Huang Pills entered mainstream retail channels in Hong Kong and Macau, overseas sales grew significantly, and the Group was named one of the Top 10 Leading Enterprises in the Overseas Expansion of Chinese Patent Medicines.

Going forward, the Group will continue to leverage its time-honoured brand, strengthen its medicinal material bases and intelligent manufacturing, deepen evidence-based research and secondary development of exclusive products, enhance its hospital, retail and overseas sales networks, and accelerate the development of a modern TCM industry system.

24. If a decision regarding dividend has been made:

- (a) Whether an interim (final) ordinary dividend has been declared (recommended)**
- (b) The amount per share, as well as for the previous corresponding period**
- (c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated)**
- (d) The date the dividend is payable**
- (e) The date on which Registrable Transfers received by the company (up to 5.00 pm) will be registered before entitlements to the dividend are determined**

If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.

No dividend has been declared for the current financial period reported on. The Company will conduct a review at the end of the financial year.

Please refer to Note 5 above for details of the dividends in respect of FY2025 that were paid during the current financial period reported on.

25. Related party transactions

There are transactions and arrangements between the Group and its subsidiaries and associates, and the effects of these transactions as determined between the parties are reflected in these condensed consolidated interim financial statements. The related company balances and transfer of resources, services or obligations (if any) are unsecured, without fixed repayment terms and interest or charge unless stated otherwise.

Intra-group transactions and balances that have been eliminated in these condensed consolidated interim financial statements are not disclosed as related party transactions and balances below.

In addition to the transactions and balances disclosed elsewhere in the notes to the financial statements, this item includes the following:

	<u>9-month period ended 30 September</u>	
	<u>2026</u> RMB'000	<u>2025</u> RMB'000
Sale of goods to associates	200,615	56,033
Purchase of goods from associates	(20,750)	(15,858)
Interest income from an associate	11,964	9,546
Interest expense payable to an associate	-	-
Rental income from an associate	3,391	-

	<u>9-month period ended 30 September</u>	
	<u>2026</u> RMB'000	<u>2025</u> RMB'000
Sale of goods to related companies	100,257	372,042
Purchase of goods from related companies	(9,733)	(8,405)
Rental expenses to related companies	(2,096)	(2,344)
Rental income from related companies	-	162

26. Interested Person Transaction disclosure

The Group has obtained a general mandate (the “**IPT General Mandate**”) from the Shareholders for interested person transactions (the “**IPTs**”, and each, an “**IPT**”) at the annual general meeting held on 15 May 2026 for FY2025. Please refer to the annexure dated 30 April 2026 accompanying the notice of annual general meeting in relation to the proposed renewal of the IPT General Mandate (as set out on pages 176 to 201 of the Company’s annual report for FY2025) for further details. During the current financial period reported on, there are no IPTs (excluding transactions less than S\$100,000) entered into with the mandated interested persons that are conducted under the IPT General Mandate.

Shareholders’ approval was also obtained for the Company’s entry into a financial services agreement with Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司) (“**TPGF**”) as an IPT and all transactions arising therefrom at the annual general meeting held on 15 May 2026 for FY2025. Please refer to the annexure dated 30 April 2026 (the “**30 April 2026 Annexure**”) accompanying the notice of annual general meeting in relation to the foregoing IPT for further details. For the avoidance of doubt, the Company has sought and obtained Shareholders’ approval for its entry into the aforesaid financial services agreement as a specific IPT. Therefore, the value of transactions conducted thereunder is not disclosed as transactions covered under the IPT General Mandate pursuant to Rule 920 of the Listing Manual.

Accordingly, the aggregate value of all IPTs during the current financial period reported on (excluding transactions less than S\$100,000) is as follows:

Name of Interested Person	Nature of relationship	Aggregate value of all interested person transactions during the financial period under review (excluding transactions less than S\$100,000 and transactions conducted under shareholders’ mandate pursuant to Rule 920 of the Listing Manual)		Aggregate value of all interested person transactions conducted during the financial period under review under a shareholders’ mandate pursuant to Rule 920 of the Listing Manual (excluding transactions less than S\$100,000)	
		9-month period ended 30 September 2026	9-month period ended 30 September 2025	9-month period ended 30 September 2026	9-month period ended 30 September 2025
		RMB’000	RMB’000	RMB’000	RMB’000
Tianjin Pharmaceutical	Subsidiary of Tianjin				

Group Finance Co., Ltd. (天津医药集团财务有限公司) (i.e. TPGF)	Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) (“TPH”), the controlling shareholder of the Company	The interest payable on the credit facilities provided by TPGF: -	-	-	-
Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司) (“ TJZX Medicine ”)	Subsidiary of Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) (“ Taiping Medicine ”), in which the Company and TPH hold 43.35% and 56.65%, respectively	Provision of guarantee by the Company for TJZX Medicine: 366,069	164,312	-	-
Taiping Medicine	Subsidiary of TPH	Provision of guarantee by the Company for Taiping Medicine: 125,444	-	-	-
Taiping Medicine	Subsidiary of TPH	Rent payable by Taiping Medicine: 14,786	14,786	-	-
Taiping Medicine	Subsidiary of TPH	Maximum aggregate fees payable to Taiping Medicine under the Warehousi			

		ng and Logistics Cooperation Agreement: 19,000	-	-	-
Taiping Medicine and TJZX Medicine	<p>Taiping Medicine is a subsidiary of TPH.</p> <p>TJZX Medicine is a subsidiary of Taiping Medicine, in which the Company and TPH hold 43.35% and 56.65%, respectively</p>	<p>Maximum aggregate value of products to be supplied to Taiping Medicine and TJZX Medicine under the Annual Distribution Agreement: 113,000</p>	-	-	-
Total		638,299	179,098	-	-

Note(s):

- (1) As at 30 September 2026, the placement of deposit with TPGF amounted to approximately RMB 1,453.81 million.
- (2) For the avoidance of doubt, the rent payable by Taiping Medicine disclosed above represents the total rent payable over the full term of the lease agreement entered into between the Company and Taiping Medicine, with a lease term from 1 July 2025 to 30 June 2028, and does not represent a new or additional transaction entered into during the current financial period reported on. This amount was originally disclosed by the Company in its second quarter of FY2025 results announcement and has continued to be reflected in the Company's subsequent periodic disclosures. It is repeated here for continuity of disclosure and information purposes only.
- (3) During the current financial period reported on, the Company, through its Health Technology Industry Development Branch (健康科技产业发展分公司), entered into the following agreements:
 - (a) a warehousing and logistics cooperation agreement (委托储存三方物流合作协议) (the “**Warehousing and Logistics Cooperation Agreement**”) with Taiping Medicine for a term commencing on the date of its execution and ending on 30 June 2028, pursuant to which the aggregate fees payable to Taiping Medicine shall

not exceed RMB 19 million; and

- (b) an annual distribution agreement (年度经销协议) (the “**Annual Distribution Agreement**”) with Taiping Medicine and TJZX Medicine for a term commencing on the date of its execution and ending on 31 December 2026, pursuant to which the aggregate value of the products to be supplied to Taiping Medicine and TJZX Medicine shall not exceed RMB 113 million (inclusive of tax).

As disclosed in the 30 April 2026 Annexure, TPGF shall provide certain financial services to the Company under the aforesaid financial services agreement, including deposit services.

As further disclosed in the 30 April 2026 Annexure, the deposit services provided by TPGF will enhance the Company's fund management and utilisation of available funds, as:

- (i) TPGF provides secure and efficient online banking services, enabling the Company to monitor its account balances and fund movements in a timely manner;
- (ii) payments and settlements may be conducted efficiently through TPGF's internal transfer mechanisms, facilitating convenient fund transfers between the Company and its branches; and
- (iii) TPGF is able to provide timely credit support to the Company, thereby reducing the need for the Company to maintain excessive cash reserves.

In this regard, as disclosed in the 30 April 2026 Annexure, the Company shall open a deposit account with TPGF and, on a free deposit and withdrawal basis, place its funds into the deposit account maintained with TPGF. Further, the maximum daily balance in the deposit account (including accrued interest) shall not exceed RMB 1,500 million. Please refer to the 30 April 2026 Annexure for further details on the scope and terms of the financial services provided by TPGF to the Company under the aforesaid financial services agreement.

Shareholders' approval for the Company's entry into the aforesaid financial services agreement was obtained at the annual general meeting of the Company held on 15 May 2026 for FY2025.

The deposit of approximately RMB 1,454 million placed with TPGF as at 30 September 2026 falls within the limit of RMB 1,500 million. Further details on the deposit are set out below:

Unit: RMB '000

Duration of deposit	Current deposit (1-7 days)	Fixed deposit (12 months)	Fixed deposit (12 months - 36 months)	Total
Balance of deposit	1,143,814.71	120,000.00	190,000.00	1,453,814.71

Note: The Company may withdraw the "current deposit" at any time and may only withdraw the

"fixed deposit" after its maturity.

Pursuant to Rule 904 of the Listing Manual, an "interested person transaction" means a transaction between an entity at risk and an interested person, and "transaction" includes, amongst others, the provision or receipt of goods or services, whether or not in the ordinary course of business, and whether or not entered into directly or indirectly (for example, through one or more interposed entities). As TPGF is a subsidiary of TPH, the controlling shareholder of the Company, the deposit services provided by TPGF to the Company constitute an IPT. However, the deposit of approximately RMB 1,453.81 million placed with TPGF as at 30 September 2026 has not been included in the IPT table set out above to prevent confusion to Shareholders. Due to the nature of deposit, the monies deposited in the account can be withdrawn and/or deposited as and when necessary, save as disclosed above in relation to fixed deposit and subject to the maximum daily balance limit as stated above. As such, it is not calculated across a financial period, and the Company is of the view that it is more meaningful to disclose the amount of the deposit placed with TPGF as at the end of the financial period under review. Accordingly, this disclosure has been presented separately from the IPT table set out above.

27. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1) of the Listing Manual

The Company confirms that it has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1) of the Listing Manual.

28. Person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13) of the Listing Manual

Pursuant to Rule 704(13) of the Listing Manual, the Company confirms that, to the best of its knowledge, belief and information, as of the date hereof, none of the persons occupying managerial positions in the Company or any of its principal subsidiaries is a relative of a Director, Chief Executive Officer or Substantial Shareholder of the Company.

29. Statement pursuant to Rule 705(5) of the Listing Manual

The Board of Directors confirm that, to the best of their knowledge, nothing has come to the attention of the Board of Directors which may render the unaudited interim consolidated financial results for the financial period ended 30 September 2026, to be false or misleading in any material respect.

30. Additional information required on acquisitions and realisations pursuant to Rule 706A of the Listing Manual

As disclosed in Note 4 above, for the current financial period reported on, the Group had not disposed of shares resulting in a company ceasing to be a subsidiary or an associated company of the Company and had also not disposed of shares resulting in the Company reducing its shareholding percentage in a subsidiary or an associated company.

As disclosed in Note 6 above, for the current financial period reported on, the Group had not acquired any shares of a company resulting in such company becoming a subsidiary or an associated company of the Company and had also not acquired any shares resulting in the Company increasing its shareholding percentage in a subsidiary or an associated company.